HIV and AIDS Trial, Recruiting NCT01730131 Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT01730131
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

This trial has three groups. Please read the section that may apply.


Group 1: People with PML (a serious brain infection)

Who might be able to join this trial:

  • People with a suspected or confirmed diagnosis of PML
  • People whose MRI brain scan shows results consistent with PML
  • People who are able to take part in the study visits and any required follow-up appointments
  • People who are at least 2 years old

Who may not be able to join:

  • People with a serious health condition that, in the lead investigator's judgement, would make taking part in the study unsafe or impossible (confirm with trial site)
  • People who cannot safely have an MRI scan — for example, those with a cardiac pacemaker, infusion pump, other metal implants, metal foreign objects, or body piercings that cannot be removed
  • People who are pregnant
  • People who are unable to give informed consent themselves and do not have a legally authorised representative who can do so on their behalf
  • People who are unwilling to consent to having biological samples (such as blood) collected and stored frozen for research

Group 2: People at Risk of PML (control group)

Who might be able to join this trial:

  • People who are able to take part in the study visits and any required follow-up appointments
  • People who are at least 2 years old
  • People with a weakened immune system from any cause who are considered at risk of developing PML — for example, those with a history of blood cancer, chronic inflammatory disease, treatment with immune-suppressing or immune-modifying medications, or a primary or acquired immune deficiency condition

Who may not be able to join:

  • People with a serious health condition that, in the lead investigator's judgement, would make taking part in the study unsafe or impossible (confirm with trial site)
  • People who cannot safely have an MRI scan — for example, those with a cardiac pacemaker, infusion pump, other metal implants, metal foreign objects, or body piercings that cannot be removed
  • People who are pregnant
  • People who are unable to give informed consent themselves and do not have a legally authorised representative who can do so on their behalf
  • People who are unwilling to consent to having biological samples (such as blood) collected and stored frozen for research

Group 3: Healthy Volunteers

Who might be able to join this trial:

  • People who are able to take part in the study visits and any required follow-up appointments
  • People who are at least 18 years old

Who may not be able to join:

  • People with a weakened immune system — for example, those with a history of blood cancer, chronic inflammatory disease, treatment with immune-suppressing or immune-modifying medications, or a primary or acquired immune deficiency condition
  • People with a serious health condition that, in the lead investigator's judgement, would make taking part in the study unsafe or impossible (confirm with trial site)
  • People who cannot safely have an MRI scan — for example, those with a cardiac pacemaker, infusion pump, other metal implants, metal foreign objects, or body piercings that cannot be removed
  • People who are pregnant
  • People who are unable to give informed consent themselves and do not have a legally authorised representative who can do so on their behalf
  • People who are unwilling to consent to having biological samples (such as blood) collected and stored frozen for research

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Irene CM Cortese, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Phone: (301) 496-3825

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 November 2012
Est. completion
1 January 2052

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To characterize the baseline presentation of patients with JCV infection and/or PML with regard to clinical, radiological, immunological, genetic and viral features.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov